Success Story: We Helped a Cancer Biology Expert Achieve I-140 NIW Approval for AI-Driven Personalized Cancer Treatment Research
Client’s Testimonial:
"The team is very helpful, promptly responding to my inquires an providing regular updates.”
On May 26th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Associate in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Postdoctoral Associate
Country of Origin: Egypt
State of Residence at the Time of Filing: New York
Approval Notice Date: May 26th, 2026
Processing Time: 13 months, 29 days (Premium Processing Upgrade Requested)
Case Summary:
The client, an expert in cancer biology with a Ph.D. in medical research, received approval of the I-140 NIW petition for work at the intersection of cancer biology, machine learning, multi-omics analysis, and personalized medicine.
Why the Endeavor Mattered
The petition framed the client’s endeavor as both medically significant and nationally important because it addresses the need for more precise and effective approaches to acute myeloid leukemia, a serious cancer with substantial clinical challenges. We emphasized that the client’s work was not limited to laboratory inquiry, but instead connected biomarker discovery, AI-based prediction, and personalized treatment strategies to broader healthcare goals.
The petition also demonstrated the client’s significance by tying the research to critical and emerging technology areas, including artificial intelligence, machine learning, multi-omics analysis, bioinformatics, computational biology, and predictive modeling. This helped show that the client’s proposed work supports both public health improvement and U.S. leadership in advanced biomedical technologies.
Evidence of a Well-Positioned Researcher
To establish that the client was well-positioned to advance the endeavor, we highlighted a focused record of cancer biology research supported by publication, citation, peer review, and funding evidence. The client has authored 6 peer-reviewed journal articles, including 1 first-authored article and 1 accepted article, as well as 1 first-authored abstract and 1 preprint. These materials reflected continued engagement with cancer biomarkers, oncogenic pathways, tumor microenvironment research, and predictive modeling.
The client’s publications had received 101 citations. Rather than presenting the citation count as self-evidently sufficient, the petition explained how citations may reflect independent reliance by other researchers. The petition also emphasized that 2 of the client’s papers ranked among the top 20% most-cited articles in their field and publication years, helping contextualize the citation record for adjudicative review.
Peer Trust and External Validation
The petition further showed that the client’s expertise had been recognized through at least 17 completed peer reviews. This service helped demonstrate that journals and editors trusted the client to evaluate the work of other researchers, which supported the argument that the client had gained recognition as a knowledgeable contributor in cancer biology and related biomedical research.
We also included evidence that the client’s research had received support from major cancer-focused funding sources, including the National Cancer Institute and Deutsche Krebshilfe. This funding evidence helped show that the client’s research aligned with serious institutional priorities in cancer research and carried value beyond ordinary academic publication.
Expert Endorsements
The petition was also supported by 2 letters of recommendation from experts in the field. These letters helped explain the significance of the client’s research record, the relevance of the client’s proposed endeavor, and the ways in which the client’s prior work positioned the client to continue contributing to cancer biology and personalized treatment development.
“It is imperative that she be allowed to carry out her research uninterrupted so that the U.S. is able to benefit fully from its value.”
A Strong NIW Outcome
Through the I-140 NIW petition, we demonstrated that the client’s advanced education, specialized cancer biology expertise, AI-driven research plan, publication record, citation impact, peer review service, funding support, and expert endorsements collectively established a strong case for national interest waiver approval. The approval recognizes the value of the client’s continued work in developing data-driven, personalized approaches for cancer treatment and improving patient outcomes.
We congratulate the client on this important I-140 NIW approval and wish the client continued success in advancing cancer biology research and AI-supported personalized medicine.